TRAVERE THERAPEUTICS, INC. Business Combination, Liabilities Arising from Contingencies, Amount Recognized
TRAVERE THERAPEUTICS, INC. (TVTX) had Business Combination, Liabilities Arising from Contingencies, Amount Recognized of $1.50 million as of 2014-12-31, per its 10-K filed 2015-03-11.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized · last filed 2015-03-11
- 2014-12-31: Business Combination, Liabilities Arising from Contingencies, Amount Recognized $1.50M.
- 2014-09-30: Business Combination, Liabilities Arising from Contingencies, Amount Recognized $1.50M.
| Period end | Business Combination, Liabilities Arising from Contingencies, Amount Recognized |
|---|---|
| 2014-12-31 | $1.50M 10-K · filed 2015-03-11 |
| 2014-09-30 | $1.50M 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |